Venrock is a multi-stage venture capital firm originally founded in 1969 as the venture arm of the Rockefeller family, investing primarily in early-stage technology and healthcare companies at the seed and Series A stages. With a track record that includes iconic portfolio companies such as Apple, Intel, Gilead Sciences, and Illumina, Venrock most recently closed a $650 million fund focused on innovation-driven businesses across AI, defense, enterprise technology, and life sciences.
“Claude Code and new AI infra solutions make it easier than ever to completely rebuild Harvey or Legora in short order, while giving [firms] full control over the user experience, functionality, workflows and, most importantly, their data. — Ethan Batraski, GP, Venrock”
“Candid Therapeutics... Acquired by UCB for up to $2.2B”
“Kelonia's last round was a Series A in 2022 at a $104 million post-money valuation — making the $3.25B upfront (and up to $7B total) a staggering markup”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.